Replies to post #185928 on NorthWest Biotherapeutics Inc (NWBO)

[Extremist223]

Why is HPD happening?

[exwannabe]

CI long term OS:

5 Year OS 34% on CIs vs 16% no CI

That is not some subset, it is every treated melanoma patient. Responder or not.

Same article:

The overall survival rate for all patients fell from about 63 percent after 12 months to a little over one-third after four years, and then plateaued. Such flattening out is indicative of a long-term benefit in some patients, although more followup is needed, Hodi said.

And how about this article on advanced 2nd line NSCLC who are PD-L1 +

Treatment with pembrolizumab (Keytruda) could elicit long-term survival (LTS) rates of 21% to 25% for previously-treated patients with PD-L1–positive non–small cell lung cancer (NSCLC) compared with 3% to 4% for docetaxel, according to a statistical analysis of findings from the KEYNOTE-010 and -001 trials presented at the 2017 ASCO-SITC Symposium.1

We estimate that among patients with previously-treated PD-L1–positive NSCLC treated with pembrolizumab the long-term survival is around 25%," said co-lead investigator Matthew D. Hellmann, MD, from the Memorial Sloan Kettering Cancer Center. "These aren't just numbers on a curve or dots on a plot, these are patients that we see who continue to do well years after starting pembrolizumab. The lives and expectations of these folks is remarkably changing

I could dig up many more where the OS curves show the same. The tail is big and fat.

As far as response rate, why do you keep harping on Rescist response rates for CI, and say they do not matter for agetnts such as DCVax-L?